Glaxosmithkline Pharmaceuticals is currently trading at Rs. 2807.00, up by 7.80 points or 0.28% from its previous closing of Rs. 2799.20 on the BSE.
The scrip opened at Rs. 2806.45 and has touched a high and low of Rs. 2832.25 and Rs. 2798.65 respectively. So far 357 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 3515.95 on 05-Jun-2025 and a 52 week low of Rs. 1924.30 on 03-Feb-2025.
Last one week high and low of the scrip stood at Rs. 2864.00 and Rs. 2753.25 respectively. The current market cap of the company is Rs. 47410.82 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 12.59% and 12.41% respectively.
Glaxosmithkline Pharmaceuticals has forayed into Indian Oncology market with the launch of Jemperli (dostarlimab) and Zejula (niraparib). To empower patients to access these innovative therapies, the company is introducing — Phoenix, a patient support program. Jemperli is the first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer, in India. Jemperli works by blocking the PD-1 pathway, a mechanism that cancer cells use to evade immune detection, thereby enabling immune cells to recognise and attack the tumour more effectively.
Zejula is the only PARP inhibitor approved as first-line monotherapy maintenance for all biomarker types in advanced ovarian cancer, in India. It offers a once-daily oral dose, making it a simple and convenient option for patients. The updated ad-hoc analysis of the phase-3 PRIMA trial demonstrated that Zejula first-line maintenance monotherapy provided durable, long-term remission in women with newly diagnosed advanced ovarian cancer. These women were at high risk for disease progression or death across all biomarker subgroups. The molecules launched are supported by robust global clinical evidence and approvals from across 40+ countries including the US, UK and EU. In India, the company is participating in ongoing oncology clinical trials aimed to extend the indication of dostarlimab to other cancers including non-small cell lung, head and neck and colorectal.
Glaxosmithkline Pharmaceuticals is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company’s Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
Glaxosmithkline Pharmaceuticals trades marginally higher on the bourses
